Edgewise Therapeutics (EWTX) Expected to Post Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Edgewise Therapeutics to announce earnings of ($0.5218) per share and revenue of $119.23 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.06). On average, analysts expect Edgewise Therapeutics to post ($2.09) EPS for the current fiscal year and ($1.78) EPS for the next fiscal year.

Edgewise Therapeutics Trading Down 1.1%

EWTX opened at $37.68 on Wednesday. The business’s 50 day moving average is $41.08 and its 200-day moving average is $36.34. The stock has a market cap of $4.09 billion, a PE ratio of -20.37 and a beta of 0.39. Edgewise Therapeutics has a twelve month low of $16.70 and a twelve month high of $48.51.

Insider Activity at Edgewise Therapeutics

In other news, CMO Joanne Donovan sold 2,919 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $43.41, for a total value of $126,713.79. Following the completion of the sale, the chief marketing officer directly owned 8,625 shares of the company’s stock, valued at approximately $374,411.25. This represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan Russell sold 5,901 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $43.73, for a total transaction of $258,050.73. Following the transaction, the insider owned 31,466 shares in the company, valued at $1,376,008.18. This represents a 15.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 38,329 shares of company stock valued at $1,675,529 over the last quarter. Corporate insiders own 21.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on EWTX. Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, October 4th. Oppenheimer started coverage on Edgewise Therapeutics in a research report on Thursday, July 9th. They set an “outperform” rating and a $51.00 price target for the company. JPMorgan Chase & Co. increased their price target on Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, The Goldman Sachs Group increased their price target on Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.33.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.